Citations

Clear

4847 citation(s) found for "Tu, Eric".

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer
Metzger, Otto , Ballman, Karla V. , Campbell, Jordan D., Liu, Minetta C. , Ligibel, Jennifer A. , Watson, Mark A. , Chen, Eveline , Du, Lili, Carey, Lisa A. , Kirshner, Jeffrey, Muss, Hyman B. , Hudis, Clifford A. , Metzger Filho, Otto , Ballman, Karla , Campbell, Jordan, Liu, Minetta , Ligibel, Jennifer A , Watson, Mark , Du, Lili , Stover, Daniel G , Carey, Lisa A , Partridge, Ann H , Muss, Hyman , Hudis, Clifford , Winer, Eric , Norton, Larry , Symmans, W Fraser , Stover, Daniel G. , Partridge, Ann H. , Winer, Eric P. , Norton, Larry , Symmans, W. Fraser

Mayo Clinic

Journal of Clinical Oncology | January 2, 2025 | Volume: 43 | Issue: 10 | Pages: 1229-1239

10.1200/jco-24-01875 | PMID 39746162 Get It

PURPOSE In light of evolving evidence that some patients with node-positive estrogen receptor–positive (ER+) disease may receive less benefit from chemotherapy, this study reports 12-year outcomes of the C9741 trial overall, and by the sensitivity to endocrine therapy (SET2,3) test index, a biomarker measuring endocrine transcriptional activity, to identify patients most likely to benefit from dose-dense chemotherapy. METHODS In all, 1,973 patients were randomly assigned to dose-dense versus conventional chemotherapy. Hazard ratios (HRs) for prognosis and for predictive interaction with chemotherapy schedule were estimated from Cox models of long-term disease-free survival (DFS) and overall survival (OS). SET2,3 was tested on the 682 banked RNA samples from ER+ cancers. RESULTS Dose-dense chemotherapy improved DFS in the overall study population by 23% (HR, 0.77 [95% CI, 0.66 to 0.90]) and OS by 20% (HR, 0.80 [95% CI, 0.67 to 0.95]); the benefits of dose-dense therapy were seen for ER+ and ER-negative subsets, without significant interaction between treatment arm and ER status. Low SET2,3 status was highly prognostic, but also predicted improved outcomes from dose-dense chemotherapy (interaction P = .0998 for DFS; 0.027 for OS), independent of menopausal status. Specifically, low endocrine transcriptional activity predicted benefit from dose-dense chemotherapy, whereas tumor burden and proliferation-driven signatures for molecular subtype classification did not. CONCLUSION At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who benefited from dose-dense chemotherapy, and specifically, this benefit was predicted by low endocrine activity in the cancer, rather than tumor burden, molecular subtype, or menopausal status.
Comparative Analysis of Injury and Illness Rates Among Team USA Athletes at the Tokyo 2020 Summer Olympic and Paralympic Games
Post, Eric G. , Cali, Malia G. , Clark, Stephanie C., Noble-Taylor, Kayle E., Robinson, David M. , Hasley, Ike B., Larson, Emily G., McPherson, April L. , Adams, William M. , Adams, William M , Clark, Stephanie C., Robinson, David M., Anderson, Travis , Finnoff, Jonathan T.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | January 2, 2025 | Volume: 13 | Issue: 1 | Pages: No page available

10.1177/23259671241304417 | PMID 39758142 Get It

Background: Previous research has reported higher rates of both injury and illness among Paralympic athletes compared with Olympic athletes during the Winter Olympic and Paralympic Games, but no studies have directly compared injury and illness incidence between Olympic and Paralympic athletes competing in a Summer Games. Purpose: To compare injury and illness rates between Olympic and Paralympic Team USA athletes competing in the Tokyo 2020 Olympic and Paralympic Games. Study Design: Descriptive epidemiology study. Methods: All injuries and illnesses that occurred among the Team USA athletes competing in the Tokyo 2020 Summer Olympic or Paralympic Games were documented. A total of 701 Team USA athletes (53.6% female) competed in the Tokyo 2020 Summer Olympic Games, across 34 different sports. For the Tokyo 2020 Summer Paralympic Games, a total of 245 athletes (51.6% female) competed across 20 sports. Incidence rates (IRs) per 1000 athlete-days were calculated according to sex, sport, anatomic location, and illness type. IR ratios (IRRs) were calculated to compare IRs between male and female athletes and between Olympic and Paralympic athletes. Results: Overall, there were no differences in injury incidence (IRR, 1.18; 95% CI, 0.84-1.68) or illness incidence (IRR, 0.68; 95% CI, 0.41-1.15) between Olympic and Paralympic athletes. Male Paralympic athletes were less likely to sustain an illness compared with female Paralympic athletes (IRR, 0.35; 95% CI, 0.11-0.90). Conclusion: There were no differences in injury or illness rates between Olympic and Paralympic Team USA athletes competing at the Tokyo 2020 Summer Games, contrary to previous comparisons among winter sport athletes. These results challenge the prevailing notion that Summer Paralympic athletes are at greater injury and illness risk, suggesting that factors beyond Olympic or Paralympic Games participation influence health concerns.
FITNESS AND TIME OF MUTATION ACQUISITION A BETTER PREDICTOR OF OUTCOME IN CLONAL HEMOPOIESIS COMPARED TO CLONE SIZE
Crespo, Tamir Chandra Neil Robertson Eric, Kirschner, Kristina , Cox, Simon R. , Schumacher, Linus

Mayo Clinic

Innovation in Aging | January 1, 2025 | Volume: 8 | Issue: Supplement_1 | Pages: 445-445

10.1093/geroni/igae098.1448 Get It

Abstract The prevalence of clonal hematopoiesis of indeterminate potential (CHIP) in healthy individuals increases rapidly from age 60 onwards and has been associated with increased risk for malignancy, heart disease and ischemic stroke. CHIP is driven by somatic mutations in stem cells that are also drivers of myeloid malignancies. We previously reported gene specific fitness effects in two longitudinal cohorts of aging. We now set out to define fitness effects across three longitudinal cohorts of aging in a total of 713 participants. We found that fitness correlates with timing of mutations, which needs to be taken into account when predicting health outcomes. We show that fitness and the time of mutations are superior predictors of outcomes such as all-cause mortality compared to the commonly used clone size (variant allele frequency). Our new predictor even outperforms age, the most important predictor for the onset of age-related disease thus far. In conclusion, the fitness landscape of mutations and their context in terms of clonal composition and timing of mutation acquisition are important parameters to bring CH predictors into the clinic.
Evaluating the factor structure of the Wechsler Adult Intelligence Scale, Fourth Edition (WAIS-IV) in adults with congenital heart disease
Dawkins-Henry, Onella S. , Bernstein, Jane Holmes, Bellinger, David C., Gurvitz, Michelle , Cassidy, Adam R. , Semmel, Eric S, Semmel, Eric S. , Wypij, David , Calderon, Johanna , Newburger, Jane W.

Mayo Clinic

The Clinical Neuropsychologist | December 31, 2024 | Volume: 39 | Issue: 7 | Pages: 2021-2032

10.1080/13854046.2024.2442424 | PMID 39741381 Get It

Expanding Upon Genomics in Rare Diseases: Epigenomic Insights
Tan, Jia W. , Blake, Emily J. , Farris, Joseph , Klee, Eric W. , Farris, Joseph D, Klee, Eric W , Tan, Jia Wen

Mayo Clinic

International Journal of Molecular Sciences | December 27, 2024 | Volume: 26 | Issue: 1 | Pages: 135

10.3390/ijms26010135 | PMID 39795993 Get It

DNA methylation is an essential epigenetic modification that plays a crucial role in regulating gene expression and maintaining genomic stability. With the advancement in sequencing technology, methylation studies have provided valuable insights into the diagnosis of rare diseases through the various identification of episignatures, epivariation, epioutliers, and allele-specific methylation. However, current methylation studies are not without limitations. This mini-review explores the current understanding of DNA methylation in rare diseases, highlighting the key mechanisms and diagnostic potential, and emphasizing the need for advanced methodologies and integrative approaches to enhance the understanding of disease progression and design more personable treatment for patients, given the nature of rare diseases.
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
Bekaii‐Saab, Tanios , Cercek, Andrea , Heinemann, Volker , Raghav, Kanwal Pratap Singh, Yoshino, Takayuki, Ramos, Jorge , Guan, Xuesong, André, Thierry , Bekaii-Saab, Tanios S , Strickler, John H. , Nakamura, Yoshiaki, Siena, Salvatore , Tabernero, Josep , Cutsem, Eric Van , Yoshino, Takayuki , André, Thierry

Mayo Clinic

Future Oncology | December 26, 2024 | Volume: 21 | Issue: 3 | Pages: 303-311

10.1080/14796694.2024.2441101 | PMID 39723627 Get It

Implementing the 2024 ACC/AHA Multisocietal PAD guidelines into clinical practice: Key changes from the 2016 guidelines
Cohoon, Kevin P. , Henkin, Stanislav , Tomihama, Roger T. , Thomas, Sneha , Porres‐Aguilar, Mateo , Brunton, Nichole , Hornacek, Deborah , Secemsky, Eric A. , Brunton, Nichole E , Porres-Aguilar, Mateo , Tomihama, Roger , Henkin, Stanislav , Secemsky, Eric A

Mayo Clinic

Vascular Medicine | December 23, 2024 | Volume: 30 | Issue: 1 | Pages: 110-113

10.1177/1358863x241306354 | PMID 39713878 Get It

Management of Relapses in Giant Cell Arteritis
Unizony, Sebastian , Murgia, Giuseppe, Prieto‐González, Sergio , Salvarani, Carlo , Matteson, Eric L. , Kermani, Tanaz A. , Alba, Marco A , Salvarani, Carlo , Matteson, Eric L , Warrington, Kenneth J.

Mayo Clinic

Arthritis & Rheumatology | December 23, 2024 | Volume: 77 | Issue: 6 | Pages: 632-645

10.1002/art.43098 | PMID 39711085 Get It

Giant cell arteritis (GCA) is a relapsing large vessel vasculitis with risk of serious ischemic manifestations, including vision loss and vascular damage in the form of large artery stenosis, aneurysms, and dissections. Approximately 50% of patients treated with glucocorticoid (GC) monotherapy and 30% of patients receiving adjunctive therapy with tocilizumab experience disease relapses, often during the first 2 years after diagnosis. Although most relapses in GCA do not involve life‐ or organ‐threatening presentations and can be controlled successfully, frequent relapses may lead to increased prescription of GC and consequent treatment‐related morbidity, in addition to risk of further vascular damage. Emerging data suggest that persistent disease activity may lead to increased vascular morbidity. Additionally, although tocilizumab decreases the frequency of relapses, more than 50% of patients relapse after discontinuation of therapy. Therefore, although interleukin‐6 blockade suppresses disease activity, it does not restore tolerance. In this article, we discuss the practical diagnosis and management of GCA relapses from an expert perspective. Current treatment options for GCA relapses, including those recommended by international guidelines, and novel potential therapies are reviewed.